

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10088801
Filing Date	2002-03-21
First Named Inventor	Fionula Mary Brennan
Art Unit	1644
Examiner Name	Zachary S. Skelding
Attorney Docket Number	20020113.ORI

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
			<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10088801
Filing Date	2002-03-21
First Named Inventor	Fionula Mary Brennan
Art Unit	1644
Examiner Name	Zachary S. Skelding
Attorney Docket Number	20020113.ORI

1	Yoshizaki et al, SPRINGER SEMIN IMMUNOPATHOL, Therapy of Rheumatoid Arthritis by Blocking IL-6 Signal Transduction with a Humanized Anti-IL-6 Receptor Antibody, Vol. 20, 1998, pp. 247-259	<input type="checkbox"/>
2	Helfrich et al, INT. J. CANCER, Construction and Characterization of a Bispecific Diabody for Retargeting T Cells to Human Carcinomas, Vol. 76, 1998, pp. 232-239	<input type="checkbox"/>
3	Contreras et al, TRANSPLANTATION, Peritransplant Tolerance Induction With Anti-CD3-Immunotoxin, Vol. 65, No. 9, May 15, 1998, pp. 1159-1169	<input type="checkbox"/>
4	Faherty et al, THE JOURNAL OF IMMUNOLOGY, Failure of IL-1 Receptor Antagonist and Monoclonal Anti-IL-1 Receptor Antibody to Inhibit Antigen-Specific Immune Responses In Vivo, Vol. 148, No. 3, February 1, 1992 pp. 766-771 (All References Previously Submitted)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.